Related Experiment Video
Updated: May 10, 2025
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Regulatory T cells: a promising new therapeutic target in ventricular remodeling after myocardial infarction
Yiran Qin1, Mingxuan Li2, Haibo Liu1
1Department of Cardiology, Qingpu Hospital Affiliated to Fudan University, Shanghai, China.
Insights
Regulatory T cells (Tregs) are key immune cells that help repair heart damage after myocardial infarction (MI). Modulating Tregs offers promising therapeutic strategies for improving cardiac function post-MI.
Area of Science:
- Immunology
- Cardiology
- Regenerative Medicine
Background:
- Myocardial infarction (MI) is a major global cause of death, leading to heart dysfunction and adverse remodeling due to cardiomyocyte death and scar tissue formation.
- Immune responses, particularly involving regulatory T cells (Tregs), significantly influence post-MI outcomes.
- Understanding Treg functions is crucial for developing new treatments for heart repair.
Purpose of the Study:
- To review the immunoregulatory roles of Tregs in post-myocardial infarction (MI) cardiac remodeling.
- To explore the mechanisms by which Tregs modulate the cardiac environment after MI.
- To discuss the potential clinical applications and challenges of Treg-based therapies for post-MI recovery.
Main Methods:
- Literature review of preclinical and clinical studies on regulatory T cells (Tregs) and myocardial infarction (MI).
- Analysis of Treg-mediated mechanisms including anti-inflammatory effects, promotion of angiogenesis, and regulation of cardiac fibroblasts.
- Synthesis of current knowledge on Treg modulation strategies for cardiac repair.
Main Results:
- Tregs play a critical role in mitigating adverse cardiac remodeling post-MI by suppressing inflammation and promoting tissue repair.
- Key mechanisms include inhibiting inflammatory cell infiltration, promoting anti-inflammatory macrophages, reducing apoptosis, and enhancing angiogenesis.
- Treg modulation presents a promising therapeutic avenue for improving cardiac function after MI.
Conclusions:
- Regulatory T cells (Tregs) are vital for cardiac repair following myocardial infarction (MI) through diverse immunomodulatory functions.
- Targeting Tregs offers significant therapeutic potential for improving post-MI ventricular remodeling and function.
- Further research into the precise molecular mechanisms of Tregs is needed to fully realize their clinical application in treating heart disease.
Abstract:
Myocardial infarction (MI) is one of the leading causes of death worldwide. It is triggered by thrombosis or vascular occlusion. After MI, damaged cardiomyocytes are replaced by scar tissue, leading to systolic and diastolic dysfunction, followed by adverse remodeling. Regulatory T cells (Tregs), as major immune cells, play a crucial role in post-MI inflammation and immunomodulation. Tregs improve cardiac remodeling after MI through various mechanisms, including inhibiting inflammatory cell infiltration, inducing anti-inflammatory macrophages, suppressing cell apoptosis, regulating fibroblast function, and promoting angiogenesis. The modulation of Tregs number or function may provide novel methods for improving post-MI remodeling. This review describes the immunoregulatory roles of Tregs, their regulatory mechanisms in post-MI ventricular remodeling, and the prospects and challenges for clinical application. However, the exact molecular mechanisms of Tregs in ventricular remodeling remain to be investigated. Although most of the current studies are at the preclinical stage, they hold great potential for further application in the future.
